Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT02815007 | Unknown Phase 2 DMC

• 1 other identifier: CancerIHCAMS
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Chidamide with EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Conditions

Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (2)

• Objective Remission Rate

  through study completion, an average of 15 months

• Disease Control Rate

  through study completion, an average of 15 months

Secondary Outcomes (11)

• Progression free survival

  through study completion, an average of 15 months

• Duration of Remission

  through study completion, an average of 15 months

• Overall Survival

  through study completion, an average of 15 months

• Time to Progression

  through study completion, an average of 15 months

• Vital signs

  Every 2 weeks for the first 6 months, every month for the remaining 6 months

Study Arms (1)

Chidamide with EGFR-TKI

EXPERIMENTAL

Chidamide: Per Os, 30mg (5mg\*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast. EGFR-TKI: Taken according to the instruction book

Drug: Chidamide with EGFR-TKI

Interventions

Chidamide with EGFR-TKI DRUG

Chidamide and EGFR-TKI, dosage described in arm description.

Also known as: Epidaza，HBI-8000

Chidamide with EGFR-TKI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Stage IIIB/IV non-small cell lung carcinoma with EGFR 19/21 point mutation, verified by histology or cytology.
• Achieved remission (CR or PR) over previous EGFR-TKI treatment; or achieved stable disease (SD) ≥ 6 months over previous EGFR-TKI treatment; disease progression emerged during the following EGFR-TKI treatment (within the past 30 days); no other treatment employed after the withdrawn of EGFR-TKI.
• Age ≥18 years, male or female;
• Has at least 1 measurable focus according to RECIST criteria 1.1, which has not been treated by radiotherapy.
• General condition should be ECOG 0-2, expected survival ≥ 3 months.
• Organ functions should fit the following:
• Bone marrow: absolute neutrophil count ≥1.5 × 109/L, platelet ≥100 × 109/L, Hb ≥ 90g/L; Liver: Total bilirubin ≤ 1.5 times of the normal maximum, ALT and AST≤ 2.5 times of the normal maximum. (ALT/AST≤ 5 times of the normal maximum for patients with infiltrative liver disease) Coagulation: INR or PT ˂ 1.5 folds of the normal maximum; Serum creatinine ˂ 1.5 folds of the normal maximum; creatinine clearance rate ≥50ml/min (calculated by Cockroft-Gault10 formula), for underweight patients, or whose results differ largely from the two formula, other methods for creatinine clearance rate calculation should be employed, like the EDTA method, inulin clearance method or 24 hour urine analysis.
• For patients with metastatic brain disease, their symptoms should be well controlled by regional therapy (surgery or radiotherapy), and no need for hormone maintenance therapy.
• For fertile women, urine or blood pregnancy test should be negative within 7 days prior to the treatment, all patients (male and female) should have contraceptive measures during the whole treatment period and 4 weeks after the treatment; willing to sign the written consent and be enrolled in the trial, and adhere to the treatment and follow up protocol.

You may not qualify if:

• Non-small cell lung carcinoma that has not been treated by EGFR-TKI.
• Patients that have taken other un-authorized medicine or medicine from other trials within 30 days before the 1st day of this trial.
• Patients with active hemorrhage or new thrombotic disorders, or those who is taking anti-coagulation drugs or those with hemorrhagic tendencies.
• History of surgery of visceral organs within 6 weeks before the trial.
• Patients' organ conditions:
• Metastatic brain/ meningeal disorders (except for those whose symptoms are well controlled by regional therapy, and no need for hormone maintenance therapy).
• Patients with history of mesenchymal lung disease, drug-induced mesenchymal disease, hormone-required radiation pneumonia, idiopathic lung fibrosis in baseline CT scan, uncontrolled massive pleural effusion or pericardial effusion.
• Patients with evidence of severe or uncontrolled systemic disease (like unstable or non-compensated respiratory/cardiac/hepatic/renal disease), according to the judgment of the researchers.
• Any unstable systemic disease (including ˃ CTCAE 2 active clinical infection, level IV hypertension, unstable angina pectoris, congestive heart failure, QT interval ˃450ms, HIV infection, metabolic liver or kidney disease); History of any malignant tumor within 5 years prior to the trial. Definitive history of neural or mental disorders, including seizure or dementia.
• Patients with xenogenic organ transplantation, patients had severe injury or massive surgery 4 weeks prior to the 1st dosage admission of medicine in the trial.
• Women during pregnancy or lactation.
• Allergic constitution, like those who are allergic to ≥2 foods or drugs, or allergic to the components of the medicine used in the trial;
• Any condition that impairs the patients' ability to swallow, and any condition that impairs drug absorption or drug kinetic parameters, including any kind of gastrointestinal resection or surgery;
• Patients with drug abuse, or any medical, psychological, social conditions that may impair trial process or the evaluation of the results of the trial;
• Any condition that may influence the safety or compliance of the patients.

Sponsors & Collaborators

• Yuankai Shi: lead

MeSH Terms

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide

Study Officials

• Yuankai Shi, Doctor

  Cancer institute and hospital, Chinese academy of medical sciencees

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yuankai Shi, Doctor

CONTACT

86-015821531560; drshiyuankai@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: June 19, 2016
• First Posted: June 28, 2016
• Study Start: June 1, 2016
• Primary Completion: March 1, 2018
• Study Completion: June 1, 2018
• Last Updated: June 28, 2016

Record last verified: 2016-06